Acorda Therapeutics Inc (ACORQ)

[Michel]

Amprya is still doing better than expected and will rack up 75-85 of sales in the US 2021. Famprya is sold by Biogen in Europe and totaled 100 million in 2020. Inbrija has more challenges, but still totaled 24 million sales in 2020 and sales 35-38 in 2021 in the US And now, with the new contract from Spain and the approval of GBA rebates in Germany, Acorda is in an excellent position to negotiate with Biogen or others for other sales outside the US in other countries